Published in PLoS One on March 14, 2013
Study of GSK1363089 in Metastatic Gastric Cancer | NCT00725712
Ockham's razor for the MET-driven invasive growth linking idiopathic pulmonary fibrosis and cancer. J Transl Med (2016) 1.38
MET in gastric cancer - discarding a 10% cutoff rule. Histopathology (2015) 0.98
MerTK inhibition is a novel therapeutic approach for glioblastoma multiforme. Oncotarget (2014) 0.98
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget (2015) 0.97
Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther (2014) 0.97
HER2 therapies and gastric cancer: a step forward. World J Gastroenterol (2013) 0.96
Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discov (2016) 0.94
Absolute quantitation of Met using mass spectrometry for clinical application: assay precision, stability, and correlation with MET gene amplification in FFPE tumor tissue. PLoS One (2014) 0.94
c-Met as a Target for Personalized Therapy. Transl Oncogenomics (2015) 0.92
HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget (2014) 0.92
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. Onco Targets Ther (2014) 0.91
Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia (2015) 0.91
Genomic alterations in advanced esophageal cancer may lead to subtype-specific therapies. Oncologist (2013) 0.90
Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Oncotarget (2015) 0.89
Second-line treatment of metastatic gastric cancer: Current options and future directions. World J Gastroenterol (2015) 0.86
How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist (2014) 0.85
Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports (2015) 0.84
Clinical significance of MET in gastric cancer. World J Gastrointest Oncol (2015) 0.83
MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget (2014) 0.83
c-Met signaling in the development of tumorigenesis and chemoresistance: potential applications in pancreatic cancer. World J Gastroenterol (2014) 0.83
Role of the tumor microenvironment in the pathogenesis of gastric carcinoma. World J Gastroenterol (2014) 0.83
Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. Br J Cancer (2015) 0.81
New advances in targeted gastric cancer treatment. World J Gastroenterol (2016) 0.81
Promise and challenges on the horizon of MET-targeted cancer therapeutics. World J Biol Chem (2015) 0.80
Inhibition of the GAS6/AXL pathway augments the efficacy of chemotherapies. J Clin Invest (2016) 0.79
Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol (2016) 0.79
Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas. BMC Cancer (2015) 0.78
Gastric Cancer: New Drugs - New Strategies. Gastrointest Tumors (2015) 0.78
MET-targeted therapy for gastric cancer: the importance of a biomarker-based strategy. Gastric Cancer (2015) 0.78
Hepatocyte Growth Factor from a Clinical Perspective: A Pancreatic Cancer Challenge. Cancers (Basel) (2015) 0.77
Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application. Gastroenterol Res Pract (2016) 0.77
Targeted therapies in gastric cancer treatment: where we are and where we are going. Invest New Drugs (2016) 0.77
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer. Oncotarget (2015) 0.77
c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations. Oncotarget (2015) 0.76
Adjuvant therapy for gastric cancer: what have we learned since INT0116? World J Gastroenterol (2015) 0.75
Translating pharmacodynamic biomarkers from bench to bedside: analytical validation and fit-for-purpose studies to qualify multiplex immunofluorescent assays for use on clinical core biopsy specimens. Semin Oncol (2016) 0.75
MET: roles in epithelial-mesenchymal transition and cancer stemness. Ann Transl Med (2017) 0.75
Novel Targeted Therapies for Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol (2016) 0.75
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Cancer (2016) 0.75
c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and medical implications. Cell Commun Signal (2017) 0.75
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants. BMC Immunol (2017) 0.75
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer. Cancer Chemother Pharmacol (2017) 0.75
Foretinib Enhances the Radiosensitivity in Esophageal Squamous Cell Carcinoma by Inhibiting Phosphorylation of c-Met. J Cancer (2017) 0.75
Clinical Development of c-MET Inhibition in Hepatocellular Carcinoma. Diseases (2015) 0.75
Underlying Mechanisms for Distant Metastasis - Molecular Biology. Visc Med (2017) 0.75
Targeted therapies for gastric cancer: failures and hopes from clinical trials. Oncotarget (2017) 0.75
Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression. Chonnam Med J (2017) 0.75
De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach. J Mol Model (2016) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
The biology of VEGF and its receptors. Nat Med (2003) 32.13
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci U S A (2006) 5.23
Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A (2004) 4.17
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A (2007) 4.08
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med (2007) 2.90
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene (2000) 2.35
Frequent amplification of the c-met gene in scirrhous type stomach cancer. Biochem Biophys Res Commun (1992) 2.11
Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res (2009) 2.08
Advanced gastric cancer--slow but steady progress. Cancer Treat Rev (2010) 1.79
Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res (2008) 1.78
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Gains, losses, and amplifications of genomic materials in primary gastric cancers analyzed by comparative genomic hybridization. Genes Chromosomes Cancer (1999) 1.68
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells. Mol Cancer Ther (2008) 1.52
MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res (2010) 1.51
MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.42
Amplification of the c-met, c-erbB-2 and epidermal growth factor receptor gene in human gastric cancers: correlation to clinical features. Oncology (1998) 1.29
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther (2011) 1.26
Mapping of chromosomal imbalances in gastric adenocarcinoma revealed amplified protooncogenes MYCN, MET, WNT2, and ERBB2. Genes Chromosomes Cancer (1998) 1.23
Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol (2001) 1.23
c-Met expression in gastric cancer with liver metastasis. Oncology (2002) 1.16
Chemotherapy for gastric cancer. World J Gastroenterol (2006) 1.13
Amplification of growth factor receptor genes and DNA ploidy pattern in the progression of gastric cancer. Virchows Arch (1997) 1.11
Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet (2010) 26.48
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res (2004) 21.36
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet (2012) 13.89
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 11.72
Global burden of childhood pneumonia and diarrhoea. Lancet (2013) 9.28
Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med (2014) 5.65
Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell (2005) 5.51
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature (2014) 5.30
ESPRIT: estimating species richness using large collections of 16S rRNA pyrosequences. Nucleic Acids Res (2009) 4.93
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 4.71
Maternal deaths averted by contraceptive use: an analysis of 172 countries. Lancet (2012) 4.65
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol (2012) 4.58
Plants and people from the Early Neolithic to Shang periods in North China. Proc Natl Acad Sci U S A (2007) 4.30
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol (2012) 3.71
Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA (2007) 3.62
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Targeting the c-Met signaling pathway in cancer. Clin Cancer Res (2006) 3.57
Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med (2011) 3.52
Distinct memory traces for two visual features in the Drosophila brain. Nature (2006) 3.48
High-speed graphene transistors with a self-aligned nanowire gate. Nature (2010) 3.48
Drosophila PIWI associates with chromatin and interacts directly with HP1a. Genes Dev (2007) 3.46
Complete genome sequence of citrus huanglongbing bacterium, 'Candidatus Liberibacter asiaticus' obtained through metagenomics. Mol Plant Microbe Interact (2009) 3.33
Evolutionary diagnosis method for variants in personal exomes. Nat Methods (2012) 3.32
Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health (2013) 3.30
Hormones and menopausal status as predictors of depression in women in transition to menopause. Arch Gen Psychiatry (2004) 3.13
Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 3.10
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
OGG1 initiates age-dependent CAG trinucleotide expansion in somatic cells. Nature (2007) 3.03
Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Lancet (2013) 3.02
Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol (2007) 3.00
Ending of preventable deaths from pneumonia and diarrhoea: an achievable goal. Lancet (2013) 2.98
Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell (2013) 2.94
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet (2011) 2.85
Anesthesia leads to tau hyperphosphorylation through inhibition of phosphatase activity by hypothermia. J Neurosci (2007) 2.68
Neuronal transcriptome of Aplysia: neuronal compartments and circuitry. Cell (2006) 2.61
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol (2012) 2.61
Rare complete knockouts in humans: population distribution and significant role in autism spectrum disorders. Neuron (2013) 2.45
Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China. PLoS Med (2006) 2.37
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 2.29
Genome-wide association analysis identifies new lung cancer susceptibility loci in never-smoking women in Asia. Nat Genet (2012) 2.26
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther (2012) 2.21
Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer (2010) 2.20
Ultraflat graphene. Nature (2009) 2.16
A dynamic gene expression atlas covering the entire life cycle of rice. Plant J (2009) 2.15
Algal genomes reveal evolutionary mosaicism and the fate of nucleomorphs. Nature (2012) 2.15
Identifying major depression using whole-brain functional connectivity: a multivariate pattern analysis. Brain (2012) 2.15
Nuclear factor high-mobility group box1 mediating the activation of Toll-like receptor 4 signaling in hepatocytes in the early stage of nonalcoholic fatty liver disease in mice. Hepatology (2011) 2.13
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol (2013) 2.13
Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabetic peripheral neuropathy. Diabetes Res Clin Pract (2013) 2.12
VAC14 nucleates a protein complex essential for the acute interconversion of PI3P and PI(3,5)P(2) in yeast and mouse. EMBO J (2008) 2.08
Cleavage specificity of Saccharomyces cerevisiae flap endonuclease 1 suggests a double-flap structure as the cellular substrate. J Biol Chem (2002) 2.06
Low prevalence of knee and back pain in southeast China; the Shantou COPCORD study. J Rheumatol (2004) 2.06
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (2004) 2.03
The aftermath of hip fracture: discharge placement, functional status change, and mortality. Am J Epidemiol (2009) 2.02
Neural synchronization during face-to-face communication. J Neurosci (2012) 1.99
Hospital episodes and physician visits: the concordance between self-reports and medicare claims. Med Care (2007) 1.96
The risks of adverse neonatal outcome among preterm small for gestational age infants according to neonatal versus fetal growth standards. Pediatrics (2003) 1.95
Identification and expression analysis of alternatively spliced isoforms of human interleukin-23 receptor gene in normal lymphoid cells and selected tumor cells. Immunogenetics (2005) 1.95
Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther (2007) 1.94
A treatment-resistant default mode subnetwork in major depression. Biol Psychiatry (2012) 1.94
Therapeutic misconception, misestimation, and optimism in participants enrolled in phase 1 trials. Cancer (2012) 1.94
Improved breast cancer prognosis through the combination of clinical and genetic markers. Bioinformatics (2006) 1.93
Activation of telomerase by human cytomegalovirus. J Natl Cancer Inst (2009) 1.92
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res (2010) 1.92
Biosynthesis of the salinosporamide A polyketide synthase substrate chloroethylmalonyl-coenzyme A from S-adenosyl-L-methionine. Proc Natl Acad Sci U S A (2009) 1.91
The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet (2010) 1.90
Proarrhythmic risk of embryonic stem cell-derived cardiomyocyte transplantation in infarcted myocardium. Heart Rhythm (2010) 1.89
GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet (2012) 1.86
Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. Development (2005) 1.85
A regulatory toolbox of MiniPromoters to drive selective expression in the brain. Proc Natl Acad Sci U S A (2010) 1.85
Coordinated redistribution of leukocyte LFA-1 and endothelial cell ICAM-1 accompany neutrophil transmigration. J Exp Med (2004) 1.85
Molecular diagnosis and therapy of kidney cancer. Annu Rev Med (2010) 1.82
Next-generation companion diagnostics: promises, challenges, and solutions. Arch Pathol Lab Med (2015) 1.81
MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res (2011) 1.80
Etiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis (2008) 1.80
Small misfolded Tau species are internalized via bulk endocytosis and anterogradely and retrogradely transported in neurons. J Biol Chem (2012) 1.79
Nucleoside analogue can improve the long-term prognosis of patients with hepatitis B virus infection-associated acute on chronic liver failure. Dig Dis Sci (2010) 1.78
Identification of open reading frames unique to a select agent: Ralstonia solanacearum race 3 biovar 2. Mol Plant Microbe Interact (2006) 1.77
Onset of breast and pubic hair development and menses in urban chinese girls. Pediatrics (2009) 1.76
HIV/STD prevalence among men who have sex with men in Chengdu, China and associated risk factors for HIV infection. J Acquir Immune Defic Syndr (2010) 1.76
Long-term retinal function and structure rescue using capsid mutant AAV8 vector in the rd10 mouse, a model of recessive retinitis pigmentosa. Mol Ther (2010) 1.75
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor. N Engl J Med (2015) 1.75
Telomerase reconstitution immortalizes human fetal hepatocytes without disrupting their differentiation potential. Gastroenterology (2003) 1.74
Involvement of reductive stress in the cardiomyopathy in transgenic mice with cardiac-specific overexpression of heat shock protein 27. Hypertension (2010) 1.73
Highly efficient gate-tunable photocurrent generation in vertical heterostructures of layered materials. Nat Nanotechnol (2013) 1.72
Reduced cytotoxic function of effector CD8+ T cells is responsible for indoleamine 2,3-dioxygenase-dependent immune suppression. J Immunol (2009) 1.72
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin Cancer Res (2010) 1.71
Age-specific effects of hormone therapy use on overall mortality and ischemic heart disease mortality among women in the California Teachers Study. Menopause (2011) 1.67
Adjuvant Therapy for Stage II and III Colon Cancer: Consensus Report of the International Society of Gastrointestinal Oncology. Gastrointest Cancer Res (2007) 1.66
Regulation of leukemic cell adhesion, proliferation, and survival by beta-catenin. Blood (2002) 1.65
Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet (2012) 1.64
Prevalence and rates of recognition of depressive disorders in internal medicine outpatient departments of 23 general hospitals in Shenyang, China. J Affect Disord (2008) 1.63
HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer. Clin Cancer Res (2008) 1.63
Evidence of the existence of the low-density liquid phase in supercooled, confined water. Proc Natl Acad Sci U S A (2006) 1.62
Atmospheric oxygen binding and hole doping in deformed graphene on a SiO₂ substrate. Nano Lett (2010) 1.62